Floatz logo

Maralixibat

Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc.Small moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Progressive Familial Intrahepatic Cholestasis cohort.

Asset / SponsorPhaseRating
ODEVIXIBAT
Albireo
Phase 1CCC
Questran
Albireo
Phase 1CC
[14c]-a4250
Albireo
Phase 1CC
Cholestyramine
Albireo
Phase 1CC

Same molecule, other indications

Maralixibat is also rated in:

Alagille syndromeActive
BBB
Indicative · Phase 2
72 / 100
View asset →
cholestasisActive
BB
Indicative · Phase 3
64 / 100
View asset →
primary sclerosing cholangitisDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →